NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
Phase 3
Completed
- Conditions
- Pre-diabetes
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00312130
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
Phase 2
Completed
- Conditions
- Pandemic Influenza Disease
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 520
- Registration Number
- NCT00311480
- Locations
- 🇮🇹
G. D'Annunzio University, Chieti, Italy
🇮🇹University Hospital of Siena, Siena, Italy
🇮🇹Department of Health Sciences, Genoa, Italy
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
Phase 4
Completed
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 179
- Registration Number
- NCT00311493
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 582
- Registration Number
- NCT00311740
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 270
- Registration Number
- NCT00311428
- Locations
- 🇫🇮
University of Tampere Medical School, Tampere, Finland
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
Phase 4
Completed
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00311441
SPP100 Dose Finding Study in Japan
Phase 2
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00311012
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
Phase 3
Completed
- Conditions
- Prevention of Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00310674
- Locations
- 🇮🇹
Istituto di Pediatria, Università degli Studi di Milano, Milano, Italy
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Phase 4
Completed
- Conditions
- Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2006-10-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 241
- Registration Number
- NCT00310635
- Locations
- 🇩🇪
Mainz, Kehl, Traunreut, Mühldorf am Inn, Bad Sobernheim, Bad Kreuznach, Baldham, Speyer,, Oppenheim,, Kempten, Germany
Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00310648
- Locations
- 🇨🇳
Nanning, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath